Cero Therapeutics Holdings, INC. (CEROW) — DEF 14A Filings

All DEF 14A filings from Cero Therapeutics Holdings, INC.. Browse 5 Proxy Statement reports with AI-powered summaries and risk analysis.

DEF 14A Filings (5)

CERO THERAPEUTICS Proposes Reverse Split, Dilutive Issuance, and Share Increase — Nov 28, 2025 Risk: high
CERO THERAPEUTICS HOLDINGS, INC. (CEROW) is convening a Special Meeting of Stockholders on December 19, 2025, to address critical strategic and financial propos
Cero Therapeutics Holdings Files Proxy Statement — May 7, 2025 Risk: low
Cero Therapeutics Holdings, Inc. filed its definitive proxy statement on May 7, 2025, for its annual meeting on May 29, 2025. The company, formerly known as Pho
Cero Therapeutics Holdings Files Definitive Proxy Statement — Oct 15, 2024 Risk: low
Cero Therapeutics Holdings, Inc. filed its definitive proxy statement on October 15, 2024, for its annual meeting of stockholders. The company, formerly known a
Cero Therapeutics Holdings DEF 14A Filing — Aug 26, 2024 Risk: low
Cero Therapeutics Holdings, Inc. filed a Definitive Proxy Statement (DEF 14A) on August 26, 2024, for its annual meeting on September 12, 2024. The company, for
Cero Therapeutics Holdings, Inc. Announces 2024 Special Meeting of Stockholders — Apr 15, 2024 Risk: low
CERO THERAPEUTICS HOLDINGS, INC. (CEROW) filed a Proxy Statement (DEF 14A) with the SEC on April 15, 2024. The 2024 Special Meeting of Stockholders for Cero The

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX